IOVA Stock New: Contact Robbins LLP for Information About the Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. and to Learn How to Be Lead Plaintiff for the Class
Iovance Biotherapeutics(US:IOVA) Prnewswire·2025-05-28 08:52SAN DIEGO, May 27, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial-stage biopharmaceutical company which develops and commercializes cell therapies for the treatment of metastatic melanoma and other solid tumor cancers.For more information, submit a form, email attorney Aaron Dumas, ...